S

Sandoz Group AG
SIX:SDZ

Watchlist Manager
Sandoz Group AG
SIX:SDZ
Watchlist
Price: 40.6 CHF 2.4% Market Closed
Market Cap: 17.9B CHF
Have any thoughts about
Sandoz Group AG?
Write Note

Sandoz Group AG
Total Other Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Sandoz Group AG
Total Other Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Other Income CAGR 3Y CAGR 5Y CAGR 10Y
S
Sandoz Group AG
SIX:SDZ
Total Other Income
-$20m
CAGR 3-Years
-36%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Novartis AG
SIX:NOVN
Total Other Income
$230m
CAGR 3-Years
N/A
CAGR 5-Years
11%
CAGR 10-Years
N/A
Roche Holding AG
SIX:ROG
Total Other Income
-CHf189m
CAGR 3-Years
-18%
CAGR 5-Years
1%
CAGR 10-Years
-37%
No Stocks Found

Sandoz Group AG
Glance View

Market Cap
17.5B CHF
Industry
Pharmaceuticals

Sandoz Group AG, a global leader in generics and biosimilars, operates as a subsidiary of the Swiss pharmaceutical giant Novartis. Established in 1886, Sandoz has a storied history rooted in innovation and a commitment to providing high-quality and affordable medications. The company's mission focuses on improving patient access to essential treatments, making it a critical player in the healthcare landscape. With a diverse portfolio of over 1,000 generic pharmaceuticals and a growing range of biosimilars, Sandoz strategically positions itself to meet the increasing global demand for cost-effective alternatives to brand-name drugs. Its robust research and development efforts ensure that Sandoz remains at the forefront of medicinal advancements, enhancing its competitive edge in an ever-evolving market. For investors, Sandoz Group AG represents an attractive opportunity, driven by several key factors. The global generics market, valued at hundreds of billions, is projected to grow as healthcare costs rise and countries push for more budget-friendly solutions. Furthermore, Sandoz's exceptional reputation for quality and compliance has made it a trusted name among healthcare providers and patients alike. The company's efforts in biotechnology and its expanding portfolio of biosimilars position it well to capture new market segments, especially as patents for major biologics expire. With a strong foundation, a commitment to innovation, and strategic growth initiatives, Sandoz offers not just stability but also potential for significant long-term returns in the dynamic pharmaceutical industry.

SDZ Intrinsic Value
43.65 CHF
Undervaluation 7%
Intrinsic Value
Price
S

See Also

What is Sandoz Group AG's Total Other Income?
Total Other Income
-20m USD

Based on the financial report for Dec 31, 2023, Sandoz Group AG's Total Other Income amounts to -20m USD.

What is Sandoz Group AG's Total Other Income growth rate?
Total Other Income CAGR 3Y
-36%

Over the last year, the Total Other Income growth was 41%. The average annual Total Other Income growth rates for Sandoz Group AG have been -36% over the past three years .

Back to Top